Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) (NCT00704184), a randomized phase 2 study. The primary outcome is Percentage of Participants Achieving RVR.

2. Clinical Question

The trial record describes a Phase II, randomized, double-blind, parallel-group study. Its stated primary hypothesis was that one or more vaniprevir groups would have a greater proportion of participants achieving RVR than the placebo group when both were combined with Peg-IFN and ribavirin. The main statistical contrast is therefore the difference in the proportions with RVR between each vaniprevir regimen and placebo. Each dose schedule is considered separately; the record does not describe a pooled vaniprevir comparison.

3. Trial Design

This was a randomized, double-blind, parallel-group Phase II study with 95 participants enrolled overall. The registry record describes five arms: placebo plus Peg-IFN/ribavirin, and four vaniprevir dose schedules combined with Peg-IFN/ribavirin. During Week 1 to Week 4, treatment was double-blind. For all arms, the description states that open-label Peg-IFN/ribavirin continued from Week 5 to Week 48. Thus the planned treatment contrast in the primary analysis concerns the addition of vaniprevir during the initial four-week period, not a continuing blinded comparison after that period.

The primary outcome was assessed at Week 4 in the per-protocol population. That population excluded participants with clinically important deviations from protocol-specified criteria, and only participants with an HCV RNA result at the Week 4 time point were included. The efficacy denominators therefore differ by arm and are the numbers used for the posted primary endpoint: 18 for placebo, 16 for vaniprevir 300 mg twice daily, 19 for vaniprevir 600 mg twice daily, 16 for vaniprevir 600 mg once daily, and 18 for vaniprevir 800 mg once daily. These analysis counts are not the same as the overall enrollment count.

The registry record identifies the study as completed. It does not report the randomization sequence, allocation concealment procedures, stratification factors, or a detailed protocol description of the study design. The stated intervention and analysis details can therefore be described, but additional design choices should not be inferred.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: During the double-blind phase (Day 1 to Day 28), participants took Vaniprevir or Placebo in combination with Pegylated Interferon (Peg-IFN)/Ribavirin. During the open-label phase (Day 29 to Week 48), participants took Peg-IFN/Ribavirin only.

Double-Blind Treatment

Reasons for not completing this period:

Open-Label Treatment

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The Per Protocol population included all participants who did not have clinically important deviations from protocol-specified criteria. Only participants with an HCV RNA result at the Week 4 time point were included in the analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The baseline population consists of all participants treated with study medication. One participant was randomized to the placebo group but withdrew from the study prior to taking any study medication.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants Achieving RVR, measured over Week 4.

The primary endpoint was the percentage of participants achieving rapid viral response (RVR) at Week 4. RVR was defined as undetectable hepatitis C virus ribonucleic acid (HCV RNA) at that time point. The endpoint is binary at the participant level: a participant either met the stated undetectable-RNA criterion or did not. The reported percentage expresses how frequently the criterion was met within each analyzed arm.

General: an early virologic endpoint can describe the short-term response observed at a specified treatment time point. It is distinct from an outcome that measures whether a response is maintained later. The registry’s primary result addresses the Week 4 criterion; it should not be read as a direct measurement of later viral status or long-term clinical outcomes.

The analysis population is important for interpreting the percentages. The primary endpoint included only per-protocol participants with a Week 4 HCV RNA result. The registry defines this group as participants without clinically important deviations from protocol-specified criteria. It does not report how participants without a Week 4 result were handled outside that stated inclusion rule. The denominator for each arm is consequently the endpoint analysis count, not necessarily every participant enrolled or assigned to that arm.

The endpoint was used to compare each vaniprevir regimen with placebo plus the same background drugs. The stated primary hypothesis focused on whether one or more vaniprevir groups had a greater proportion achieving RVR. The posted result therefore concerns the observed Week 4 response proportions and their between-arm contrasts, not an isolated description of viral change or a claim about outcomes beyond the registry’s reported measures.

7. Results Posted in the Registry

• Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin: 75.0% (12/16) versus 5.6% (1/18) on control; risk difference 69.4 percentage points (95% CI 45.7 to 93.2), risk ratio 13.50 (1.97–92.60); unadjusted two-proportion z-test p = <0.001.
• Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin: 78.9% (15/19) versus 5.6% (1/18) on control; risk difference 73.4 percentage points (95% CI 52.2 to 94.6), risk ratio 14.21 (2.09–96.82); unadjusted two-proportion z-test p = <0.001.
• Vaniprevir 600 mg q.d. + Peg-IFN/Ribavirin: 68.8% (11/16) versus 5.6% (1/18) on control; risk difference 63.2 percentage points (95% CI 38.1 to 88.3), risk ratio 12.38 (1.79–85.53); unadjusted two-proportion z-test p = <0.001.
• Vaniprevir 800 mg q.d. + Peg-IFN/Ribavirin: 83.3% (15/18) versus 5.6% (1/18) on control; risk difference 77.8 percentage points (95% CI 57.6 to 98.0), risk ratio 15.00 (2.21–101.90); unadjusted two-proportion z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Number of Participants With ≥2-log10 Decrease in HCV RNA

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin: 100.0% (16/16) versus 88.9% (16/18) on control; risk difference 11.1 percentage points (95% CI -3.4 to 25.6), risk ratio 1.12 (0.96–1.32); unadjusted two-proportion z-test p = 0.169.
  • Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin: 100.0% (19/19) versus 88.9% (16/18) on control; risk difference 11.1 percentage points (95% CI -3.4 to 25.6), risk ratio 1.12 (0.96–1.32); unadjusted two-proportion z-test p = 0.135.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin and the control. The interval gives the range of effects that remain compatible with the data.

Number of Participants With ≥3-log10 Decrease in HCV RNA

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin: 100.0% (16/16) versus 83.3% (15/18) on control; risk difference 16.7 percentage points (95% CI -0.5 to 33.9), risk ratio 1.20 (0.98–1.48); unadjusted two-proportion z-test p = 0.087.
  • Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin: 100.0% (19/19) versus 83.3% (15/18) on control; risk difference 16.7 percentage points (95% CI -0.5 to 33.9), risk ratio 1.20 (0.98–1.48); unadjusted two-proportion z-test p = 0.063.
• Interpretation:
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin and the control. The interval gives the range of effects that remain compatible with the data.
  • The 95% confidence interval includes no difference, so these data do not show a statistically significant difference between Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin and the control. The interval gives the range of effects that remain compatible with the data.

Mean Log Change From Baseline in HCV RNA

• Endpoint type: Continuous: a mean value per participant, compared as a difference in means.
• Test: Unadjusted two-sample z-test for the difference in means, using the posted standard deviations.
• Result:
  • Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin: mean -6.10 versus -3.60 on control; difference -2.50 (95% CI -3.31 to -1.69), standardized effect d = -2.07; z-test p = <0.001.
  • Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin: mean -6.30 versus -3.60 on control; difference -2.70 (95% CI -3.38 to -2.02), standardized effect d = -2.61; z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Vaniprevir 300 mg b.i.d. + Peg-IFN/Ribavirin than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.
  • The 95% confidence interval excludes no difference, so the mean is statistically lower for Vaniprevir 600 mg b.i.d. + Peg-IFN/Ribavirin than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The secondary outcomes add two kinds of information about the Week 4 viral response: counts of participants meeting specified HCV RNA decline thresholds, and mean log change from baseline. Taken together, the posted arm summaries generally show substantial viral RNA declines during the measured period, including in the placebo plus Peg-IFN/ribavirin group. The secondary measures therefore provide context for the primary RVR endpoint, which requires an undetectable Week 4 result rather than a specified reduction from baseline.

These outcomes are related but not interchangeable. A participant can have a marked decrease in HCV RNA without meeting the undetectable-RNA definition of RVR. The continuous mean-change measure describes average change and does not show how many participants reached a particular threshold. Conversely, a threshold count does not convey the size of each participant’s change beyond whether the criterion was met.

The registry posts three secondary outcomes, and the reported analyses include only some contrasts for some outcomes. The mean-change sponsor analyses are reported for two vaniprevir arms versus placebo; the registry does not present the same sponsor comparison for every regimen. The results should be interpreted in light of this uneven reporting rather than assumed to form a complete, uniformly analyzed set of all possible arm comparisons.

Unadjusted secondary comparisons carry less inferential weight than a prespecified primary analysis, particularly when several outcomes and group contrasts are examined. General: considering many tests without an adjustment or a clearly prioritized testing strategy increases the chance that at least one apparently notable result arises by chance. The registry does not report a multiplicity strategy for the secondary outcomes. These results are useful as supporting descriptions of the response pattern, but they should not be treated as independent confirmation equivalent to the primary endpoint analysis.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Number of Participants With ≥2-log10 Decrease in HCV RNA
• Number of Participants With ≥3-log10 Decrease in HCV RNA
• Mean Log Change From Baseline in HCV RNA

9. Statistical Interpretation

10. Statistical Methods Explained

The primary endpoint is a binary outcome summarized as a percentage. For each arm, the percentage describes the proportion of analyzed participants who met the RVR definition at Week 4. A comparison between arms can be expressed as a difference in proportions, often reported in percentage points. A positive difference in this setting means that the estimated proportion achieving RVR is higher in the vaniprevir arm than in the placebo arm; it does not, by itself, establish why the difference occurred or how broadly it applies beyond the trial population.

How should the adjusted differences be read?

The registry reports the primary comparisons using the Miettinen and Nurminen method. The results are adjusted differences in percentage points, with 95% confidence intervals and p-values. The listed adjusted difference is the estimated contrast from the sponsor’s analysis; the confidence interval describes the range of values reasonably compatible with the data under that analysis and its assumptions. A confidence interval is not a guarantee that the true value falls within its endpoints, and it is not a range containing a specified proportion of individual participants.

The reported p-values are all <0.001 for the primary contrasts. A p-value is a measure of how incompatible the observed data are with a specified null hypothesis under the analysis assumptions. It is not the probability that the null hypothesis is true, nor does it measure the probability that a result will recur. Statistical evidence and the estimated size and precision of the contrast are related but distinct considerations.

What do the recalculated estimates represent?

The recalculated primary contrasts are simple, unadjusted comparisons from the posted summary counts. They use each arm’s observed number of participants meeting the endpoint and the corresponding analysis denominator. For example, the posted counts are 1 of 18 in the placebo group and 12 of 16 in the 300 mg twice-daily group. The recalculated risk difference is accompanied by an unadjusted confidence interval and p-value. The same basic approach is used for the other posted binary comparisons where those quantities are available.

These recalculations are not a reconstruction of every feature of the sponsor’s original analysis. The registry’s primary analyses are explicitly labeled adjusted differences and identify the Miettinen and Nurminen method. The summary counts alone do not identify all implementation details of that analysis. Accordingly, the sponsor’s reported adjusted results and the simple unadjusted recalculations should be kept distinct rather than treated as interchangeable estimates.

Why use a risk difference?

General: a risk difference presents an absolute contrast between two proportions, using the same percentage-point scale as the endpoint. This makes it possible to describe how far apart the observed group proportions are. Relative measures, such as a risk ratio or odds ratio, answer a different question by expressing a comparison on a multiplicative scale. When the control group has few observed events, relative estimates may be especially sensitive to the small counts and can have wide intervals. A measure should therefore be interpreted with its scale and uncertainty in mind rather than by its numerical size alone.

For the primary outcome, the sponsor’s adjusted differences are the central registry analyses. The recalculated risk differences, risk ratios, and odds ratios are unadjusted supplementary summaries based on the posted counts. Their confidence intervals and p-values do not incorporate any analysis features that are not recoverable from those counts. No claim that the recalculations reproduce the sponsor’s model is warranted.

What do the secondary analyses add?

The secondary outcome results include participant counts meeting thresholds for HCV RNA decline and mean log change from baseline. For the binary threshold outcomes, the same general idea of comparing proportions applies. For the continuous mean-change outcome, the comparison concerns arm averages on the log scale rather than the proportion of participants meeting a threshold. The registry also reports standard deviations for the arm means, which describe spread among analyzed values; they are not confidence intervals for the means.

General: a standard deviation describes the variability of individual observations around an arm mean, whereas a confidence interval for a mean or contrast describes uncertainty in an estimated average or difference. Those quantities answer different questions. The posted mean-change comparisons use the means and standard deviations available for the reported groups, and their recalculated results are distinct from the sponsor’s reported least-squares mean contrasts.

What can the analysis population tell us?

The per-protocol primary analysis excludes participants with clinically important deviations from protocol-specified criteria and includes only those with a Week 4 HCV RNA result. Such an analysis describes outcomes in the participants meeting those conditions. It is not identical to an analysis of every randomized participant. The registry record does not report a primary intention-to-treat analysis or details of sensitivity analyses for missing Week 4 results, so neither should be presumed.

General: exclusions and missing outcome measurements can affect the population represented by an estimate. If inclusion in the analysis is related to outcome or treatment experience, the observed proportion may not fully represent all randomized participants. The registry’s stated population definition is therefore necessary context for interpreting the result, while the available record does not allow the impact of excluded or unavailable observations to be quantified.

11. Confidence Intervals and Precision

The registry’s 95% confidence intervals describe uncertainty around the adjusted differences between each vaniprevir arm and placebo. For the four primary comparisons, the reported intervals are 40.3 to 86.7 percentage points for 300 mg twice daily, 46.0 to 88.6 for 600 mg twice daily, 32.8 to 82.7 for 600 mg once daily, and 49.2 to 91.3 for 800 mg once daily. Each interval is on the adjusted difference scale and is paired with a p-value <0.001.

All four intervals lie above zero, the value corresponding to no difference on a difference scale. The intervals nevertheless cover a range of possible effect sizes, so the estimated differences are more precisely located as being positive than as having one exact magnitude. The intervals overlap one another, and the registry does not report a formal comparison among the vaniprevir regimens. Their overlap should not be used as a substitute for such a comparison.

The endpoint denominators were 16, 18, or 19 in the individual groups. With group counts of this size, a small number of participants can materially affect a proportion. General: confidence intervals express sampling uncertainty under the analysis method; they do not address every source of uncertainty, such as representativeness, measurement limitations, analysis-population selection, or unreported design details.

The simple recalculated intervals are unadjusted and differ from the sponsor’s adjusted intervals. The registry’s reported confidence intervals should be used when describing the sponsor analysis. Precision should be considered together with the definition of RVR, the Week 4 timing, and the per-protocol inclusion rule rather than in isolation.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The sample-size figures are planning illustrations expressed as participants per arm for the binary and continuous outcomes in this trial; they are not total event counts. The planning assumptions are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. The effect to detect is set at a stated fraction of the observed effect. These assumptions describe the illustration, not the original trial design, whose sample-size assumptions are not reported in the registry record.

The 80% power column gives the illustrative number of participants per arm for a design that would have an 80% chance of detecting the specified effect under the planning assumptions, if that effect and those assumptions held. The 90% power column makes the same kind of illustration for a 90% chance. Power is a property of a planned design under specified assumptions; it is not a measure of whether a completed trial has succeeded.

The rows that use 100%, 75%, or 50% of the observed effect illustrate how the required group size changes when the assumed target effect changes. For example, for the 300 mg twice-daily primary comparison, planning for 75% of the observed effect gives 12 participants per arm for 80% power and 15 participants per arm for 90% power; planning for 50% gives 22 and 29, respectively. A smaller effect is harder to distinguish from random variation, so the illustration requires more participants per arm to target it at the same power level.

These figures are not observed power. They are retrospective planning illustrations based on the observed effect, not evidence that the original trial had a particular probability of detecting an effect. The original protocol’s sample-size justification and design assumptions are not reported in the registry record. A curve based on these assumptions should be read as showing how the planning estimate changes with the assumed effect, rather than as a forecast of the result in a different trial.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.056; treatment proportion p₁ = 0.750; average p̄ = 0.403.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.6936 = 1.3595.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.4899 = 0.4123.
4. n = (1.3595 + 0.4123)² / (0.6944)² = 6.5, rounded up to 7 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.0555555555555556                          # control proportion
p1 <- 0.75                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(704184)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 7 (80% power), 9 (90% power)
 75% of observed effect: n per arm = 12 (80% power), 15 (90% power)
 50% of observed effect: n per arm = 22 (80% power), 29 (90% power)
power.prop.test: 6.5 
Simulated power at n = 7 per arm: 0.858 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Analyses Reported by the Sponsor

The registry reports four sponsor analyses of RVR, each comparing a vaniprevir regimen with placebo plus Peg-IFN/ribavirin. The method is identified as Miettinen and Nurminen, and each result is an adjusted difference in percentage points with a 95% confidence interval. The reported estimates are 69.3, 73.6, 63.3, and 77.8 percentage points for the four respective dose schedules; all four p-values are <0.001.

The recalculated comparisons use the posted counts and denominators to form simple, unadjusted risk differences and their associated uncertainty summaries. They are not the same calculation as the sponsor’s adjusted method. The sponsor’s estimates are therefore the appropriate values to quote when describing the analysis reported by the registry, while the recalculations provide a transparent summary from the arm-level counts.

The record does not flag a discrepancy between the posted arm results and the reported analyses. Differences between adjusted and unadjusted estimates should not be treated as a contradiction: they reflect different analysis presentations. The registry does not provide enough detail to reconstruct every element of the sponsor’s analysis beyond the method and results it reports.

15. Multiplicity, Missing Data and Analysis Populations

The registry identifies RVR at Week 4 as the primary endpoint and states a hypothesis comparing one or more vaniprevir groups with placebo. The posted primary analyses include four dose-versus-placebo contrasts. It also lists three secondary outcomes, while the record reports 6 outcome measures and 16 analyses overall. The registry record does not report a multiplicity adjustment, a hierarchical testing procedure, or another strategy for controlling the chance of false-positive findings across the multiple comparisons.

General: when several hypotheses are tested, the chance of observing at least one small p-value under a setting where none of the tested effects is real can increase. A prespecified testing hierarchy or multiplicity adjustment can address that issue, but no such procedure should be assumed when it is not reported. The primary p-values should therefore be understood as the reported comparison-specific values; they do not by themselves establish that family-wise error across all endpoints and contrasts was controlled.

The primary endpoint analysis population is described as per protocol. It includes participants without clinically important protocol deviations who had a Week 4 HCV RNA result. The registry record does not report an intention-to-treat primary result, the number or reasons for exclusions from the per-protocol set, or sensitivity analyses assessing the effect of missing Week 4 results. It also does not describe a missing-data imputation method. The posted endpoint denominators should be read as the analyzed counts for this outcome, not as proof that outcome data were available for every enrolled participant.

The record does not report the original sample-size justification, interim analyses, stopping rules, or detailed statistical analysis plan. It does not state whether analysis choices or secondary comparisons were prespecified beyond the described primary hypothesis and endpoint. Without those details, the reported results can be summarized, but additional claims about multiplicity control, missing-data robustness, or the timing of analysis decisions cannot be made.

These gaps do not erase the posted comparisons; they define the limits of what can be inferred about the overall testing strategy and the population represented by the per-protocol estimates. A cautious reading distinguishes the reported primary analysis from secondary and additional contrasts whose testing context is not fully described.

16. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cholecystitis acute (5.6%), appendicitis (5.6%), gastroenteritis (5.6%), lobar pneumonia (5.6%), myopathy (5.6%).

The safety summaries give the number at risk and the number affected by a serious adverse event for each arm. The recorded pairs are 1 of 19 for placebo plus Peg-IFN/ribavirin, 3 of 18 for vaniprevir 300 mg twice daily, 1 of 20 for 600 mg twice daily, 2 of 18 for 600 mg once daily, and 2 of 19 for 800 mg once daily. These are counts, not adjusted comparisons of safety between groups.

The registry also lists serious adverse event terms with their reported percentages: acute cholecystitis, appendicitis, gastroenteritis, lobar pneumonia, and myopathy at 5.6% each, and haemoglobin decreased at 5.3%. The record does not provide an arm attribution for these listed terms in the summarized information, so they should not be assigned to a specific treatment group based on these figures alone.

The death fields are not reported in the registry record. The serious-event counts should be read within the reported safety populations, whose at-risk counts differ from the primary efficacy denominators. The registry provides no adjusted safety comparison or uncertainty interval for these counts, and the small group counts make them descriptive rather than a basis for a precise comparative safety estimate.

17. What the Result Does, and Does Not, Mean

The primary result describes the proportion of per-protocol participants with undetectable HCV RNA at Week 4. In the posted analyses, each vaniprevir-plus-Peg-IFN/ribavirin arm had a higher observed RVR percentage than the placebo-plus-Peg-IFN/ribavirin arm, and each sponsor-reported adjusted difference had a 95% confidence interval above zero with p < 0.001. This is the statistical finding for the stated endpoint and analysis population.

It does not, by itself, show whether a Week 4 response was maintained after that time point. Nor does it establish an effect on outcomes not reported in the registry record. The arm descriptions state that open-label Peg-IFN/ribavirin continued through Week 48, but the primary endpoint is RVR at Week 4. Treatment duration and endpoint timing should not be confused with evidence of a later virologic outcome.

The four primary comparisons are each against the same placebo group. They do not establish that one vaniprevir dose schedule is superior to another. The record does not report a formal dose-to-dose comparison, and differences among the listed arm percentages should not be treated as proof of a dose ranking. The study was Phase II; the record’s designation and results do not establish how well the estimates would generalize to other populations or settings.

General: statistical significance is not a measure of clinical importance, and a p-value does not quantify the probability that a result is true. The size of the estimated difference, its confidence interval, the endpoint’s scope, and the analysis population all matter. The registry results provide estimates of an early virologic endpoint in this trial; they are not medical advice and do not determine an individual’s care.

The secondary outcomes give additional measures of viral RNA change, but they do not change the definition or timing of the primary endpoint. The posted safety data are descriptive and do not provide a full comparative safety analysis. Together, the results support a careful statistical description of the trial rather than a broad claim about benefit, harm, or long-term outcomes.

18. Why This Trial Matters Statistically

This trial illustrates why an endpoint definition and analysis population need to be read together. RVR is defined by undetectable HCV RNA at Week 4, and the primary result uses a per-protocol subset with a Week 4 result. A percentage without that context could be mistaken for a result among all enrolled participants or for a later outcome. The record’s explicit population definition and arm-specific denominators make the scope of the primary estimate clearer.

It also illustrates the difference between an adjusted sponsor analysis and a simple reconstruction from summary counts. The posted Miettinen and Nurminen results are adjusted differences, while recalculations from the arm counts are unadjusted. Both can describe the same broad comparison, but they answer it through different analysis presentations. Keeping those estimates labeled prevents an unadjusted calculation from being mistaken for the sponsor’s inferential analysis.

The study has four vaniprevir regimens sharing one placebo comparator. That structure is important for interpretation: each primary comparison addresses a dose schedule versus placebo, not a head-to-head dose comparison. Multiple endpoints and contrasts also raise questions about multiplicity, yet the registry record does not describe a correction or testing hierarchy. Recognizing that distinction helps separate the stated primary finding from exploratory or secondary evidence.

Finally, the confidence intervals make clear that strong evidence against a zero difference does not mean the exact magnitude is known. The estimates are based on modest arm-specific analysis counts and have appreciable ranges. The sample-size illustrations further show how planning assumptions depend on the target effect, but they are not the original design justification. These features make the record a useful example of reading effect estimates, uncertainty, analysis populations, and incomplete reporting together.

19. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
• Participant counts were reconstructed from posted percentages and arm sizes, so small rounding differences are possible.

The primary analysis includes only per-protocol participants with a Week 4 HCV RNA result. This is a narrower analysis population than all enrolled participants, and the registry record does not provide an intention-to-treat result, counts and reasons for exclusions, or sensitivity analyses for unavailable Week 4 results. The possible effect of those exclusions cannot be assessed from the reported information.

The primary arm denominators are 16, 18, or 19. Such group counts mean the observed proportions and confidence intervals are based on limited numbers of participants in each comparison. The reported intervals convey uncertainty under the sponsor’s analysis, but they do not resolve questions about external validity or the stability of estimates in other populations.

The primary outcome is an early virologic measure at Week 4. The record does not report a primary long-term virologic endpoint, and the existence of open-label Peg-IFN/ribavirin treatment through Week 48 does not establish what later outcomes were observed. The available secondary outcomes describe Week 4 viral RNA changes; they do not replace a later outcome assessment.

Four vaniprevir regimens are compared with a shared placebo arm, but the registry does not report formal dose-to-dose tests. It also does not report a multiplicity strategy for the primary contrasts and secondary analyses, or detailed statistical analysis plan information beyond the named primary method. The original sample-size justification and interim-analysis procedures are not reported in the registry record.

The safety summary gives serious-event counts and a list of terms but does not provide an adjusted comparative safety analysis or arm attribution for the listed terms. The death fields are not reported in the registry record. These limits restrict the safety interpretation to the descriptive counts and terms that are posted.

20. Related Tutorials

21. Related Statistical Calculators

22. Sources

• ClinicalTrials.gov: Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) — NCT00704184.
• Registry record last updated 2018-10-09; status last verified 2018-09.
• Results first posted 2014-10-01.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

23. Record Summary

NCT00704184 is a completed, randomized, double-blind, parallel-group Phase II study of vaniprevir combined with Peg-IFN and ribavirin in treatment-naive participants with chronic hepatitis C. The study enrolled 95 participants and compared four vaniprevir regimens with placebo during the blinded Week 1 to Week 4 period. The arm descriptions state that open-label Peg-IFN/ribavirin continued from Week 5 to Week 48.

The primary endpoint was RVR at Week 4, defined as undetectable HCV RNA, analyzed in a per-protocol population with a Week 4 result. The sponsor reported adjusted differences versus placebo using the Miettinen and Nurminen method; all four primary p-values were <0.001. The record also lists secondary viral RNA outcomes and descriptive serious adverse event counts. Details about multiplicity control, missing-data sensitivity analyses, the original sample-size justification, and deaths are not reported in the registry record.